Alzheimer’s Disease Study
Alzheimer’s is a devastating type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly in the sixth to eighth decade, and get worse over time, becoming severe enough to interfere with daily tasks. As our population ages, effective treatments to slow down and even reverse Alzheimer’s are desperately needed. At New England Institute for Clinical Research, we currently are working on just that. Our studies in this disease state include:
- A Study of Solanezumab (LY2062430) in Participants with Prodromal Alzheimer’s Disease (ExpeditionPRO).
- Lu AE58054 in Patients With Mild-moderate Alzheimer’s Disease Treated With Donepezil (STARBEAM)
- Longitudinal Evaluation of [18F]MNI-798 as a PET Radioligand for Imaging Tau in the Brain of Patients With Alzheimer’s Disease Compared to Healthy Volunteers.
- Safety and Efficacy of Piromelatine in Mild Alzheimer’s Disease Patients (ReCOGNITION)
Use the form below to enroll